Jane A.  Gross net worth and biography

Jane Gross Biography and Net Worth

Director of aTyr Pharma

Jane A. Gross, Ph.D., has served as a director since June 2019. Dr. Gross served as the Chief Scientific Officer and Senior Vice President of Research and Development of Aptevo Therapeutics Inc. (Aptevo) from September 2016 to September 2021. She currently serves as a consultant to, and on the scientific advisory boards of several biotechnology companies developing drugs for autoimmune, inflammatory and oncology therapeutics. At Aptevo, Dr. Gross led the discovery of novel protein therapeutics based on the ADAPTIR™ and ADAPTIR-FLEX™ platform technologies focusing on development of therapeutics based on immuno-oncology, leading research efforts in molecular biology and protein engineering, immunology, protein and cell sciences, pharmacology and translational research. Prior to joining Aptevo, Dr. Gross served as Vice President, Applied Research and Non-Clinical Development at Emergent BioSolutions Inc. and Vice President, Immunology Research at ZymoGenetics, Inc., where she led efforts in discovery and development of therapeutics from novel genes. Dr. Gross serves on the board of directors of BriaCell Therapeutics Corp., a biotechnology company. Dr. Gross holds a Ph.D. in immunology from the University of California, Berkeley under Jim Allison (2018 recipient of the Nobel Prize in Physiology and Medicine) and a Post-Doctoral Fellowship from the University of Washington in immunology.

What is Jane A. Gross' net worth?

The estimated net worth of Jane A. Gross is at least $8.07 thousand as of March 17th, 2025. Gross owns 9,750 shares of aTyr Pharma stock worth more than $8,071 as of December 5th. This net worth estimate does not reflect any other investments that Gross may own. Learn More about Jane A. Gross' net worth.

How do I contact Jane A. Gross?

The corporate mailing address for Gross and other aTyr Pharma executives is 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO, CA, 92121. aTyr Pharma can also be reached via phone at (858) 731-8389 and via email at [email protected]. Learn More on Jane A. Gross' contact information.

Has Jane A. Gross been buying or selling shares of aTyr Pharma?

Jane A. Gross has not been actively trading shares of aTyr Pharma in the last ninety days. Most recently, on Monday, March 17th, Jane A. Gross bought 3,750 shares of aTyr Pharma stock. The stock was acquired at an average cost of $4.00 per share, with a total value of $15,000.00. Following the completion of the transaction, the director now directly owns 9,750 shares of the company's stock, valued at $39,000. Learn More on Jane A. Gross' trading history.

Who are aTyr Pharma's active insiders?

aTyr Pharma's insider roster includes Jill Broadfoot (CFO), Nancy Denyes (General Counsel), Jane Gross (Director), and Paul Schimmel (Director). Learn More on aTyr Pharma's active insiders.

Are insiders buying or selling shares of aTyr Pharma?

In the last year, aTyr Pharma insiders bought shares 3 times. They purchased a total of 1,003,750 shares worth more than $927,719.96. In the last year, insiders at the sold shares 2 times. They sold a total of 2,153 shares worth more than $8,138.34. The most recent insider tranaction occured on October, 9th when Director Paul Schimmel bought 317,999 shares worth more than $298,919.06. Insiders at aTyr Pharma own 3.7% of the company. Learn More about insider trades at aTyr Pharma.

Information on this page was last updated on 10/9/2025.

Jane A. Gross Insider Trading History at aTyr Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/17/2025Buy3,750$4.00$15,000.009,750View SEC Filing Icon  
See Full Table

Jane A. Gross Buying and Selling Activity at aTyr Pharma

This chart shows Jane A Gross's buying and selling at aTyr Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

aTyr Pharma Company Overview

aTyr Pharma logo
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $0.83
Low: $0.75
High: $0.86

50 Day Range

MA: $0.84
Low: $0.65
High: $1.06

2 Week Range

Now: $0.83
Low: $0.64
High: $7.29

Volume

3,226,154 shs

Average Volume

3,281,441 shs

Market Capitalization

$81.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57